Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin) Association With a Fludarabine Based Reduced Conditioning Regimen [fludarabine, busulfan, antithymocyte globulin, ciclosporin and rituximab] and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2014
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Antithymocyte globulin; Busulfan; Busulfan; Ciclosporin; Fludarabine; Rituximab
- Indications Diffuse large B cell lymphoma; Graft-versus-host disease; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 20 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Mar 2008 New trial record.